New York City—January 25, 2010
“The standard treatment for lupus kidney disease is to block inflammation,” said Lionel Ivashkiv, M.D., associate chief scientific officer at Hospital for Special Surgery in New York City. “This study suggests you might want to target the macrophages, a specific type of white blood cell involved in the disease.”
For years, clinicians have known that kidney damage occurs in many patients with lupus, and they have known how the disease triggers the start of kidney disease. Little has been known, however, about one type of lupus kidney disease, proliferative crescentic disease that is associated with adverse outcomes and decreased survival. This type of kidney disease is characterized by abnormal proliferation (growth) of kidney cells that leads to irreversible damage to internal kidney structures that help filter waste and fluids from the blood. This advanced kidney disease leads to kidney failure and it is an important cause of the need for dialysis and transplantation in lupus.
Previous studies have suggested that type I interferons are implicated in promoting the autoimmunity associated with lupus. “We were interested in understanding whether these interferons might work directly on the kidney,” Dr. Ivashkiv said. “There is a lot of evidence that the interferons work on the immune system and we wanted to know how interferons affect kidney disease.”
To investigate, researchers used a mouse model of lupus. By increasing interferon production, they caused advanced kidney disease to occur in the mice rapidly. “The mice are a strain that will get nephritis over time, but we injected the mice at the very onset of the disease thus causing a very accelerated pattern, so that the mice have complete renal failure in two to four weeks,” Dr. Ivashkiv said. They then examined the changes that occurred during the development of the advanced kidney disease by drawing blood samples from the mice, and analyzing their kidneys, and analyzing the macrophages to determine their type, among other experiments.
In the type of kidney disease they were investigating, it has long been known that epithelial cells proliferating out of control form a kind of crescent. These crescent cells compress the glomerulus, the basic filtration unit of the kidney, and prevent it from functioning.
In their experiments, the investigators found that the development of these crescents was associated with infiltrating kidney macrophages that produced growth factors, and the infiltration of these was spurred by interferon type I. They also found that the type of macrophages involved were not the most common type of inflammatory macrophages but so called “alternatively activated macrophages” that are involved in wound healing and induce the proliferation of cells. This is what causes the proliferation and crescentic lesions in the kidney disease.
“This study suggests a new drug target. If you could understand how to target the macrophages and inhibit them or the growth factors that they produce, this might be a different approach to therapy,” Dr. Ivashkiv said. “This is an emerging area. Prior to this study, a role of macrophages had just been identified in lupus kidney disease, and this is the first study showing alternatively activated macrophages are involved in proliferative crescentic disease.”
The study was conducted by Dr. Lionel Ivashkiv and Dr. Antigoni Triantafyllopoulou, a rheumatology fellow at Hospital for Special Surgery. Dr. Anne Davidson, an expert in lupus models from the Feinstein Institute for Medical Research, Manhasset, N.Y., was a key collaborator. Other authors of the study are Claus-Werner Franzke, Giorgio Perino, and George D. Kalliolias from Hospital for Special Surgery; Surya V. Seshan from Weill Cornell Medical College, NewYork-Presbyterian Hospital, New York; Meera Ramanujam from the Feinstein Institute for Medical Research and Nico van Rooijen from Vrije Universiteit Medical Center in Amsterdam, The Netherlands.
About HSS | Hospital for Special Surgery
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the eighth consecutive year) and No. 3 in rheumatology by U.S. News & World Report (2017-2018). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State. In 2017 HSS provided care to 135,000 patients and performed more than 32,000 surgical procedures. People from all 50 U.S. states and 80 countries travelled to receive care at HSS. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The culture of innovation is accelerating at HSS as 130 new idea submissions were made to the Global Innovation Institute in 2017 (almost 3x the submissions in 2015). The HSS Education Institute is the world’s leading provider of education on the topic on musculoskeletal health, with its online learning platform offering more than 600 courses to more than 21,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally.